Kazia Therapeutics Limited American Depositary Shares KZIA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:55:25.664Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:54:05.020761197Z
FundamentalsAlpha Vantage · ready · quarter 2025-12-31 · fetched 2026-11-11T14:54:34.238559+00:00
Kazia Therapeutics Limited American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.03 | 157.6% | 24.4% | |||
| 25Δ | 6.33 | 160.0% | 21.5% | |||
| 30Δ | 6.64 | 162.4% | 18.7% | |||
| 35Δ | 6.95 | 164.8% | 15.8% | |||
| 40Δ | 7.26 | 167.2% | 13.0% | |||
| 45Δ | 7.58 | 170.7% | 10.5% | |||
| 50Δ | 16.97 | 800.0% | 158.6% | 8.00 | 178.4% | 9.4% |
| 55Δ | 11.79 | 676.7% | 85.0% | 8.41 | 186.1% | 8.4% |
| 60Δ | 10.33 | 682.3% | 69.6% | 8.82 | 193.9% | 7.3% |
| 65Δ | 8.32 | 593.5% | 44.0% | 9.24 | 201.6% | 6.3% |
| 70Δ | 7.14 | 507.6% | 28.8% | 9.65 | 209.3% | 5.3% |
| 75Δ | 6.56 | 440.6% | 21.7% | 10.14 | 216.9% | 4.2% |
| 80Δ | 5.98 | 373.6% | 14.7% | 11.06 | 223.6% | 3.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.03
- IV
- 157.6%
- B/E move
- 24.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.33
- IV
- 160.0%
- B/E move
- 21.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.64
- IV
- 162.4%
- B/E move
- 18.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.95
- IV
- 164.8%
- B/E move
- 15.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.26
- IV
- 167.2%
- B/E move
- 13.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.58
- IV
- 170.7%
- B/E move
- 10.5%
50Δ
- Pseudo strike
- 16.97
- IV
- 800.0%
- B/E move
- 158.6%
- Pseudo strike
- 8.00
- IV
- 178.4%
- B/E move
- 9.4%
55Δ
- Pseudo strike
- 11.79
- IV
- 676.7%
- B/E move
- 85.0%
- Pseudo strike
- 8.41
- IV
- 186.1%
- B/E move
- 8.4%
60Δ
- Pseudo strike
- 10.33
- IV
- 682.3%
- B/E move
- 69.6%
- Pseudo strike
- 8.82
- IV
- 193.9%
- B/E move
- 7.3%
65Δ
- Pseudo strike
- 8.32
- IV
- 593.5%
- B/E move
- 44.0%
- Pseudo strike
- 9.24
- IV
- 201.6%
- B/E move
- 6.3%
70Δ
- Pseudo strike
- 7.14
- IV
- 507.6%
- B/E move
- 28.8%
- Pseudo strike
- 9.65
- IV
- 209.3%
- B/E move
- 5.3%
75Δ
- Pseudo strike
- 6.56
- IV
- 440.6%
- B/E move
- 21.7%
- Pseudo strike
- 10.14
- IV
- 216.9%
- B/E move
- 4.2%
80Δ
- Pseudo strike
- 5.98
- IV
- 373.6%
- B/E move
- 14.7%
- Pseudo strike
- 11.06
- IV
- 223.6%
- B/E move
- 3.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 167.28% |
Biotechnology
LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs…
More →LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San…
More →